Type stringclasses 2
values | Section_id stringclasses 4
values | Primary_id stringlengths 11 11 | Secondary_id stringlengths 0 11 | Statement stringlengths 34 385 | Label stringclasses 2
values | Primary_evidence_index listlengths 1 65 | Secondary_evidence_index listlengths 0 73 | Primary_ct stringlengths 1.11k 16.3k | Secondary_ct stringlengths 101 16.3k | __index_level_0__ stringlengths 36 36 |
|---|---|---|---|---|---|---|---|---|---|---|
Single | Results | NCT00368875 | the primary trial results indicate that the Recommended Phase II Dose for paclitaxel, as Assessed by NCI Common Terminology Criteria for Adverse Events, is 90 mg/m2 . | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10
] | [] | {'Clinical Trial ID': 'NCT00368875', 'Intervention': ['INTERVENTION 1: ', ' Phase I', ' Vorinostat dose (200 or 300 mg BID) was assigned at the time of registration. Vorinostat was administered orally twice daily on days 1-3, 8-10, and 15-17 of each 28-day cycle.', ' All patients also received paclitaxel at 90 mg/m2... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | b250a17c-9d4d-405d-ba64-40f7eda16707 | |
Single | Adverse Events | NCT00082641 | At least one patient in the primary trial suffered from impaired mobility. | Entailment | [
8,
14
] | [] | {'Clinical Trial ID': 'NCT00082641', 'Intervention': ['INTERVENTION 1: ', ' Arm I', ' Patients receive vaccination comprising p53-infected autologous dendritic cells subcutaneously (SC) 1 week after completion of doxorubicin and cyclophosphamide, 1 week after completion of paclitaxel (or after surgery for patients wi... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 698849c5-78fa-4c15-a1dc-f44eb9c970c2 | |
Single | Adverse Events | NCT00075764 | The most common adverse event in cohort 1 of the primary trial is low Hemoglobin levels. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9
] | [] | {'Clinical Trial ID': 'NCT00075764', 'Intervention': ['INTERVENTION 1: ', ' Arm I Anastrozole', ' Patients receive oral anastrozole once daily on days 1-28.', ' anastrozole: Given orally', 'INTERVENTION 2: ', ' Arm II Anastrozole and Fulvestrant', ' Patients receive oral anastrozole as in arm I. Patients also rece... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 4b4e6ac7-107c-46f4-adbb-c77c01f51935 | |
Single | Eligibility | NCT00579826 | Participants of the primary trial cannot be currently receiving treatment for rheumatoid arthritis, experiencing poorly controlled migraines or have any prior history of invasive breast cancer in the last 3 years. | Entailment | [
6,
8,
10,
11
] | [] | {'Clinical Trial ID': 'NCT00579826', 'Intervention': ['INTERVENTION 1: ', ' Letrozole', ' Letrozole, 2.5 mg daily for 6 months', ' Letrozole: Letrozole 2.5 mg tablet daily. Then optional open label letrozole for another 6 months.', 'INTERVENTION 2: ', ' Placebo', ' Placebo, daily for 6 months', ' Placebo: Placebo... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 6b73dee4-0291-455e-90c2-786f0c2371d4 | |
Single | Results | NCT00324259 | Cohort 2 of the primary trial 3 had more patients with Complete response than cohort 1. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25
] | [] | {'Clinical Trial ID': 'NCT00324259', 'Intervention': ['INTERVENTION 1: ', ' Arm 1 (6 mg Estradiol)', ' 6 mg of estradiol daily (2 mg tid).', 'INTERVENTION 2: ', ' Arm 2 (30 mg Estradiol)', ' 30 mg of estradiol. (10 mg tid)'], 'Eligibility': ['Inclusion Criteria:', ' Postmenopausal women with advanced hormone recep... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 2a1d9064-fde9-4645-95ab-7ddaea4ad322 | |
Single | Intervention | NCT00509587 | Patients in the primary trial receive 300 mg pazopanib once daily intravenously every day, continuing until disease progression or unacceptable toxicity. | Contradiction | [
0,
1,
2,
3,
4,
5
] | [] | {'Clinical Trial ID': 'NCT00509587', 'Intervention': ['INTERVENTION 1: ', ' Treatment (Pazopanib Hydrochloride)', ' Patients receive oral pazopanib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.', ' pazopanib hydrochloride: Given orally', ' phar... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 847de3fe-b584-4d43-b82d-93263ce88830 | |
Comparison | Eligibility | NCT00149214 | NCT01004744 | Prior use of Anthracycline drugs in the last 6 months for anticancer therapy is prohibted for patients in the primary trial, but not for patients in the secondary trial. | Contradiction | [
4,
5
] | [
0,
4
] | {'Clinical Trial ID': 'NCT00149214', 'Intervention': ['INTERVENTION 1: ', ' Pemetrexed Plus Doxorubicin, Followed by Docetaxel', ' pemetrexed: 500 mg/m^2, intravenous (IV), every 21 days, 4 cycles (1-4) doxorubicin: 60 mg/m^2, intravenous (IV), every 21 days, 4 cycles (1-4) docetaxel: 100 mg/m^2, intravenous (IV), ev... | {'Clinical Trial ID': 'NCT01004744', 'Intervention': ['INTERVENTION 1: ', ' Presurgical Oral Anastrozole', ' 1mg daily for two weeks in the interval between diagnostic breast biopsy and definitive breast surgery.', ' Anastrozole: 1mg PO daily for two weeks prior to scheduled surgery'], 'Eligibility': ['Inclusion Cri... | 3c798991-6366-43e2-94ca-0523629930c2 |
Single | Adverse Events | NCT01764022 | Cohort 2 of the primary trial recorded multiple incidents of thrombocytopenia. | Contradiction | [
10,
13
] | [] | {'Clinical Trial ID': 'NCT01764022', 'Intervention': ['INTERVENTION 1: ', ' BCD-022 (CJSC BIOCAD)', ' BCD-022 is a product code for trastuzumab biosimilar manufactured by CJSC BIOCAD, Russia. In this arm patients will receive 6 courses of treatment with BCD-022 in combination with paclitaxel. Patients will receive BC... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 64fe54a2-8897-4324-af88-f627c1c208ed | |
Single | Results | NCT01328249 | The Percentage of Participants With Feasibility was 70% higher in cohort 1 of the primary trial than in cohort 2. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | [] | {'Clinical Trial ID': 'NCT01328249', 'Intervention': ['INTERVENTION 1: ', ' Cohort 1: Eribulin Mesylate With Filgrastim as Needed', " Participants initially received doxorubicin (60 mg/m^2) plus cyclophosphamide (600 mg/m^2) intravenously (IV) on Day 1, of every 14-day cycle for 4 cycles. Eribulin mesylate was admini... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 4eac6a2d-64cd-4289-a545-211eb835f0e9 | |
Comparison | Results | NCT02435680 | NCT01743560 | the secondary trial and the primary trial use best Overall Response (OR) as their evaluation metrics, however they use significantly different time frames. | Contradiction | [
0,
1,
2,
3
] | [
0,
1,
2,
3
] | {'Clinical Trial ID': 'NCT02435680', 'Intervention': ['INTERVENTION 1: ', ' All MCS110+Carboplatin+Gemcitabine', ' experimental. all MCS110 treated patients, with 10mg/kg intravenous infusion, on day 1 and days 1 & 8', 'INTERVENTION 2: ', ' Carboplatin+Gemcitabine', ' comparator. Gemcitabine: Intravenous infusion 1... | {'Clinical Trial ID': 'NCT01743560', 'Intervention': ['INTERVENTION 1: ', ' Everolimus and Exemestane', ' Postmenopausal women diagnosed with oestrogen receptor positive locally advanced or metastatic breast cancer will receive everolimus at a dose of 10mg daily p.o. and exemestane 25mg daily p.o.'], 'Eligibility': [... | 3ee1c60e-46ce-4f25-af52-31d5c6d8eba1 |
Comparison | Eligibility | NCT01340300 | NCT00671918 | Patients cannot do more than half an hour of physical exercise in a day, if they are to participate in the primary trial, however, this is not a requirement for the secondary trial. | Contradiction | [
0,
5
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25,
26,
27
] | {'Clinical Trial ID': 'NCT01340300', 'Intervention': ['INTERVENTION 1: ', ' Exercise Training With Metformin', ' Exercise training with exercise physiologist with oral metformin', ' Exercise training plus metformin: Two supervised exercise sessions per week. Oral metformin QD for 2 weeks, then BID', 'INTERVENTION 2:... | {'Clinical Trial ID': 'NCT00671918', 'Intervention': ['INTERVENTION 1: ', ' Intent-To-Treat', ' Participants received a single dose of 50 μg Lymphoseek radiolabeled with 0.5 or 1.0 mCi Tc 99m and blue dye for lymphatic mapping and surgical resection of lymph nodes.'], 'Eligibility': ['Inclusion Criteria:', ' The pat... | da1e1019-adb5-47bf-8093-e03352ca9e51 |
Single | Eligibility | NCT01042938 | Patients must be english to participate in the primary trial. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23
] | [] | {'Clinical Trial ID': 'NCT01042938', 'Intervention': ['INTERVENTION 1: ', ' Curcumin C3 Complex', ' Patients take 2.0 grams curcumin (four 500mg capsules) three times daily by mouth for prescribed course of radiation treatment (RT) (~4-7 weeks).', 'INTERVENTION 2: ', ' Placebo', ' Patients take 2.0 grams placebo (f... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | e7fb6490-1ec7-48ff-95b1-715d79faec92 | |
Comparison | Adverse Events | NCT00618826 | NCT02040857 | the primary trial and the secondary trial only record 2 of the same adverse events. | Contradiction | [
0,
3,
8,
10,
5
] | [
0,
9,
3,
6,
11
] | {'Clinical Trial ID': 'NCT00618826', 'Intervention': ['INTERVENTION 1: ', ' Treatment', ' Paclitaxel / Gemcitabine'], 'Eligibility': ['Inclusion Criteria:', ' Patient must be 18 years of age or older with histologically confirmed breast cancer and clinical evidence of metastatic disease.', ' Patients must have meas... | {'Clinical Trial ID': 'NCT02040857', 'Intervention': ['INTERVENTION 1: ', ' Palbociclib With Adjuvant Endocrine Therapy', ' Palbociclib 125 mg PO qd 21 days on, 7 days off', ' Endocrine Therapy: Tamoxifen 20mg, Letrozole 2.5mg, Anastrozole 1mg, or Exemestane 25mg PO qd'], 'Eligibility': ['Inclusion Criteria:', ' Pa... | d5ea3443-103f-4d29-9be3-522210b84152 |
Single | Eligibility | NCT00193050 | Patients must be over the age of 18 and have a life expectancy over 6 months to participate in the primary trial. | Entailment | [
0,
3,
11,
13
] | [] | {'Clinical Trial ID': 'NCT00193050', 'Intervention': ['INTERVENTION 1: ', ' Intervention', ' In the neoadjuvant setting, patients were administered gemcitabine (800 mg/m2 IV days 1 and 8), epirubicin (75 mg/m2 IV day 1), and docetaxel (30 mg/m2 IV days 1 and 8)repeated every 21 days for 4 cycles', ' Patients then ha... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | d54cae08-3ac9-4460-bf6d-7338b45d8cd7 | |
Single | Adverse Events | NCT00086957 | All of the patients in cohort 1 of the primary trial experienced an adverse event. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12
] | [] | {'Clinical Trial ID': 'NCT00086957', 'Intervention': ['INTERVENTION 1: ', ' Phase I: Dose Level 1 - Docetaxel 75 mg/m^2', ' Subjects receive gefitinib 250 mg orally daily, trastuzumab 6 mg/kg intravenously every 3 weeks (after an initial dose of 8 mg/kg with cycle 1), and docetaxel 75 mg/m^2 intravenously every 3 wee... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 608c5521-c9a6-47de-9ebf-791ce317a02d | |
Comparison | Eligibility | NCT00593827 | NCT00478257 | Patients with HER2 negative MBC are eligible for both the primary trial and the secondary trial. | Contradiction | [
0,
1,
2
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10
] | {'Clinical Trial ID': 'NCT00593827', 'Intervention': ['INTERVENTION 1: ', ' Ixabepilone 16 mg/m^2', ' ixabepilone 16 mg/m^2 weekly for 3 weeks followed by 1 week rest', 'INTERVENTION 2: ', ' Ixabepilone 40 mg/m^2', ' ixabepilone 40 mg/m^2 every 3 weeks'], 'Eligibility': ['Inclusion Criteria:', ' Has MBC that is me... | {'Clinical Trial ID': 'NCT00478257', 'Intervention': ['INTERVENTION 1: ', ' Effect of Bright Light', ' Effect of bright light on fatigue in women with breast cancer', 'INTERVENTION 2: ', ' Effect of Red Light', ' effect of red light on fatigue in women with breast cancer'], 'Eligibility': ['Inclusion Criteria:', ' ... | 14a8e9e9-0a46-4537-bc07-53c786bcbe97 |
Comparison | Adverse Events | NCT01048099 | NCT02502864 | the primary trial recorded 2 more total adverse events than the secondary trial | Contradiction | [
0,
1
] | [
0,
1
] | {'Clinical Trial ID': 'NCT01048099', 'Intervention': ['INTERVENTION 1: ', ' Patients Treated', ' Patients who received study treatment'], 'Eligibility': ['Inclusion Criteria:', ' Part I', ' Women with HER2-negative breast cancer, as defined by FISH testing. (FISH testing may have been performed on the primary tumor... | {'Clinical Trial ID': 'NCT02502864', 'Intervention': ['INTERVENTION 1: ', ' Standard of Care + Surveys', ' Standard of Care Docetaxel and Cyclophosphamide (TC) Chemotherapy + Surveys. TC Regimen with Function Assessment of Cancer Therapy (FACT) Surveys.'], 'Eligibility': ['Inclusion Criteria:', ' Must have histologi... | 2d97bfa0-336f-4976-95e5-1262327a730b |
Single | Results | NCT00003199 | The patient group with the highest percent of Event-free Survival in the primary trial was Stage IIIB patients, and the worst was Stage IV Disease patients. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20
] | [] | {'Clinical Trial ID': 'NCT00003199', 'Intervention': ['INTERVENTION 1: ', ' TX/Maintenance Therapy for Stage IIIB/IV Breast Cancer', ' See Detailed Description.', ' tamoxifen citrate: Given orally', ' busulfan: Given orally', ' thiotepa: Given IV', ' melphalan: Given IV', ' aldesleukin: Given SC', ' sargramosti... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | e68dddc8-ea04-49b2-ae91-ff7b4fcb1240 | |
Single | Intervention | NCT03765996 | Participants in group 2 of the primary trial receive the same Complex Decongestive Physiotherapy as those in group 1, with the addition of applying taping to anastomosis regions. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7
] | [] | {'Clinical Trial ID': 'NCT03765996', 'Intervention': ['INTERVENTION 1: ', ' Decongestive Physiotherapy', ' This group received Complex Decongestive Physiotherapy.', ' Decongestive Physiotherapy: This group received CDP, which include MLD, short-stretch bandages, lymph-reducing exercises, and skin care. MLD was appli... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 8c83330f-f2f3-48e1-9905-dc2ba1970c54 | |
Comparison | Intervention | NCT04080297 | NCT02780713 | Cohort 2 of the primary trial receives higher doses of Q-122 than either of the secondary trial cohorts receive of AZD9496 variants. | Entailment | [
3,
4,
5
] | [
0,
1,
2,
3,
4,
5
] | {'Clinical Trial ID': 'NCT04080297', 'Intervention': ['INTERVENTION 1: ', ' 100 mg Q-122', ' Dosage was 100 mg Q-122 administered orally as two 50 mg capsules once daily for 28 days.', 'INTERVENTION 2: ', ' 200 mg Q-122', ' Dosage was 200 mg Q-122 administered orally as four 50 mg capsules once daily for 28 days.']... | {'Clinical Trial ID': 'NCT02780713', 'Intervention': ['INTERVENTION 1: ', ' Treatment Period 1', ' Participants received AZD9496 - Variant A (100 mg).', 'INTERVENTION 2: ', ' Treatment Period 2', ' Participants received AZD9496 - Reference (100 mg).'], 'Eligibility': ['Inclusion Criteria:', ' Provision of signed a... | 4613834d-c178-475c-b9fd-c9c66d5681eb |
Single | Results | NCT00259090 | the primary trial studies the impact of Fulvestrant, Docetaxel on Oestrogen Receptor H-score. | Contradiction | [
1
] | [] | {'Clinical Trial ID': 'NCT00259090', 'Intervention': ['INTERVENTION 1: ', ' Fulvestrant', ' Fulvestrant 500 mg once monthly injection', 'INTERVENTION 2: ', ' Fulvestrant + Anastrozole', ' Fulvestrant 500 mg once monthly injection + Anastrozole 1 mg once daily tablet'], 'Eligibility': ['Inclusion Criteria:', ' Post... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | b4555685-6e25-4797-8616-bcab5b06a135 | |
Comparison | Eligibility | NCT00290732 | NCT02748213 | Patients whose breast tumour is 0.1 cm across or less are eligible for the secondary trial, but not the primary trial. | Contradiction | [
2,
8
] | [
0,
1
] | {'Clinical Trial ID': 'NCT00290732', 'Intervention': ['INTERVENTION 1: ', ' Intraductal Arm', ' Participants received intraductal administration of dextrose or dextrose with pegylated liposomal doxorubicin hydrochloride (or PLD) prior to conventional surgery for breast cancer.'], 'Eligibility': ['DISEASE CHARACTERIST... | {'Clinical Trial ID': 'NCT02748213', 'Intervention': ['INTERVENTION 1: ', ' Herceptin + Taxotere + Xeloda', ' Participants received triple therapy with Herceptin, Taxotere, and Xeloda until disease progression, unmanageable toxicity, or withdrawal. Herceptin and Taxotere were given via IV infusion on Day 1 of each 21... | c1b90c18-45f4-4e28-b50a-a00b0eadc523 |
Single | Eligibility | NCT00232479 | Only patients with HER2 positive breast carcinoma are eligible for the primary trial. | Entailment | [
0,
1
] | [] | {'Clinical Trial ID': 'NCT00232479', 'Intervention': ['INTERVENTION 1: ', ' Group 1', ' patients received dose dense herceptin, carboplatin and taxotere'], 'Eligibility': ['Inclusion Criteria:', ' HER-2 overexpressing breast cancer', ' Clinical stage 2-3B', ' Normal ejection fraction', 'Exclusion Criteria:', ' Me... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 33ef3abf-97c0-4d15-909d-258fb47ac54a | |
Comparison | Results | NCT01323530 | NCT01106040 | the secondary trial and the primary trial results indicate that the PFS of participants is partially linked to age, cancer grade and ethnicity. | Contradiction | [
0,
1,
2,
3
] | [
0,
1,
2,
3
] | {'Clinical Trial ID': 'NCT01323530', 'Intervention': ['INTERVENTION 1: ', ' Phase 1b (Schedule 1): Eribulin Mesilate (1.2 mg/m^2)', ' Participants received eribulin mesilate 1.2 mg/m^2, injection, intravenously, once, on Day 1 and capecitabine 1000 mg/m^2, tablets, orally, twice daily from Day 1 to 14 in each 21-day ... | {'Clinical Trial ID': 'NCT01106040', 'Intervention': ['INTERVENTION 1: ', ' Intent-To-Treat', ' Participants received a single dose of 50 μg Lymphoseek radiolabeled with 0.5 or 2.0 mCi Tc 99m and blue dye for lymphatic mapping and surgical resection of lymph nodes.'], 'Eligibility': ['Inclusion Criteria:', ' The pat... | a381e340-18b1-4baa-91ce-0c420bcb411c |
Single | Intervention | NCT00383500 | the primary trial is not testing a drug based intervention, it is testing a Medical device called Manual Lymphatic Drainage. | Contradiction | [
0,
1,
2,
3,
4,
5
] | [] | {'Clinical Trial ID': 'NCT00383500', 'Intervention': ['INTERVENTION 1: ', ' Flexitouch Device', ' Lymphedema management via Flexitouch device, an intermittent pneumatic compression device (aka, lymphedema pump)', 'INTERVENTION 2: ', ' Manual Lymphatic Drainage (MLD)', ' Lymphedema management via self-administered m... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 15e6b2b9-ba8f-4ca5-99d7-a1bbf9497b4b | |
Single | Results | NCT00436566 | Not a single patient in the primary trial suffered from Congestive Heart Failure during active treatment with Trastuzumab and RAD001. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9
] | [] | {'Clinical Trial ID': 'NCT00436566', 'Intervention': ['INTERVENTION 1: ', ' AC/PTL', ' Standard doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel (80 mg/m^2) x 12 with concurrent standard dose trastuzumab (weekly x 12, then repeat 3 weeks for an additional 9 months) plus daily lapatinib (modified to... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 8e246d8f-e063-4f2e-a382-5d201a946b87 | |
Single | Eligibility | NCT00097721 | Patients of any ethnicity can participate in the primary trial. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25,
26,
27,
28,
29,
30,
31,
32,
33,
34,
35,
36
] | [] | {'Clinical Trial ID': 'NCT00097721', 'Intervention': ['INTERVENTION 1: ', ' E7389 28 Day Schedule', ' E7389 1.4 mg/m^2 intravenous bolus on Days 1, 8 and 15 of a 28 day cycle.', 'INTERVENTION 2: ', ' E7389 21 Day Schedule', ' E7389 1.4 mg/m^2 intravenous bolus on Days 1 and 8 of a 21 day cycle.'], 'Eligibility': ['... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 8154bd8c-90a2-4b2f-8090-fcc89aeae30c | |
Single | Results | NCT02657889 | the primary trial indicates that varying Pembrolizumab dosage has no effect on the Number of Subjects Reporting Dose-Limiting Toxicities (DLTs). | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | [] | {'Clinical Trial ID': 'NCT02657889', 'Intervention': ['INTERVENTION 1: ', ' Phase 1: Niraparib 200mg + Pembrolizumab', ' Niraparib 200 mg/day orally (PO). Pembrolizumab 200 mg intravenously (IV) on Day 1 of each 21-day cycle.', 'INTERVENTION 2: ', ' Phase 1: Niraparib 300mg + Pembrolizumab', ' Niraparib 300 mg/day ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 537781f9-3693-479e-af22-824cdd827b9c | |
Single | Adverse Events | NCT02748213 | 2 patients, in cohort 1 of the primary trial was recorded as having an overactive pituitary gland. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23
] | [] | {'Clinical Trial ID': 'NCT02748213', 'Intervention': ['INTERVENTION 1: ', ' Herceptin + Taxotere + Xeloda', ' Participants received triple therapy with Herceptin, Taxotere, and Xeloda until disease progression, unmanageable toxicity, or withdrawal. Herceptin and Taxotere were given via IV infusion on Day 1 of each 21... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 5feefe8b-ddca-4eb8-af68-d1e211963d1f | |
Single | Intervention | NCT00956813 | All the primary trial subjects are required to take the intervention tablet PO daily. | Contradiction | [
0,
1,
2,
3,
4,
5
] | [] | {'Clinical Trial ID': 'NCT00956813', 'Intervention': ['INTERVENTION 1: ', ' Flaxseed', ' Patients receive 1 Nutrigrad™ flaxseed bar containing 7.5 grams flaxseed, 410 mg lignans,once daily.', 'INTERVENTION 2: ', ' Placebo', ' Patients Identical looking bar with same calorie and total fat content but without flaxsee... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 2a5d8ca7-1608-4607-b996-490fc447b593 | |
Single | Adverse Events | NCT00258960 | 4 patients in the primary trial experienced a grade 3 or above adverse event. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8
] | [] | {'Clinical Trial ID': 'NCT00258960', 'Intervention': ['INTERVENTION 1: ', ' Caelyx,Cyclophosphamide,Trastuzumab', ' Caelyx (Liposomal Doxorubicin) 50 mg/m2 every 4 weeks for 6 cycles, Cyclophosphamide 600 mg/m2 every 4 weeks for 6 cycles, Trastuzumab weekly for 24 weeks, at dose of 2mg/kg (day 1 loading dose of 4mg/k... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 178c50cc-49ee-4083-bc8e-b5832037498a | |
Comparison | Adverse Events | NCT01026142 | NCT00846027 | There were 10% more patients with Left ventricular systolic dysfunction in cohort 1 of the primary trial than in the secondary trial. | Contradiction | [
0,
7,
12,
19
] | [
0,
4
] | {'Clinical Trial ID': 'NCT01026142', 'Intervention': ['INTERVENTION 1: ', ' A: Capecitabine + Trastuzumab', ' Capecitabine [Xeloda]: 1250 mg/m2 po twice daily for 14 days every 3 weeks. Trastuzumab [Herceptin]: 8 mg/kg iv loading, then 6 mg/kg iv every 3 weeks.', 'INTERVENTION 2: ', ' B: Capecitabine + Trastuzumab +... | {'Clinical Trial ID': 'NCT00846027', 'Intervention': ['INTERVENTION 1: ', ' Bevacizumab + Paclitaxel + Gemcitabine', ' Participants received bevacizumab 10 mg/kg intravenously (IV), paclitaxel 150 mg/m^2 IV, and gemcitabine 2000 mg/m^2 IV on Day 1 and Day 15 of each 4-week cycle until disease progression, unacceptabl... | 92ace4fa-4426-4f34-af52-ee62913e60aa |
Single | Results | NCT01823107 | At most 12 Patients implanted with a Meso BioMatrix Acellular Peritoneum Matrix suffered Breast Related Adverse Events. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9
] | [] | {'Clinical Trial ID': 'NCT01823107', 'Intervention': ['INTERVENTION 1: ', ' Meso BioMatrix Acellular Peritoneum Matrix', ' All subjects had the Meso BioMatrix Acellular Peritoneum Matrix implanted along with a tissue expander during the first stage of breast reconstruction. After tissue expansion, the tissue expander... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 7dbde84d-f1c9-4197-9d44-500fd337bebd | |
Single | Adverse Events | NCT02340221 | A total of 89 patients in the primary trial had Supraventricular tachycardia. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25
] | [] | {'Clinical Trial ID': 'NCT02340221', 'Intervention': ['INTERVENTION 1: ', ' Placebo+Fulvestrant', ' Participants received placebo taken orally QD beginning at Cycle 1, Day 1, and fulvestrant 500 mg administered by IM injection at Cycle 1, Days 1 and 15, and then on Day 1 of each subsequent 28-day cycle until disease ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 824da29f-b2ff-440e-8b78-7a8291cbd6d2 | |
Single | Adverse Events | NCT02748213 | 1 patient, in cohort 1 of the primary trial was recorded as having an overactive thyroid gland. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23
] | [] | {'Clinical Trial ID': 'NCT02748213', 'Intervention': ['INTERVENTION 1: ', ' Herceptin + Taxotere + Xeloda', ' Participants received triple therapy with Herceptin, Taxotere, and Xeloda until disease progression, unmanageable toxicity, or withdrawal. Herceptin and Taxotere were given via IV infusion on Day 1 of each 21... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 6cbac938-baf2-4f0b-b67b-9caeb7ea4fe1 | |
Single | Adverse Events | NCT00244933 | the primary trial does not monitor the occurrence of Hemoglobin C Disease in its adverse events. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9
] | [] | {'Clinical Trial ID': 'NCT00244933', 'Intervention': ['INTERVENTION 1: ', ' Gemcitabine & Genistein', ' Gemcitabine, genistein (Novasoy), Tumor biopsy Gemcitabine IV-1000mg/m2: Days 1 & 8 every 21 days: Novasoy Orally-100 mg 2 times/day for 7 days; 2 times/day on Days 1-21 every 21 days.'], 'Eligibility': ['DISEASE C... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 052ee533-7daa-4cbf-a64c-bc9a50444173 | |
Single | Adverse Events | NCT00444587 | A total of 7 patients in the primary trial were observed with either Leukopenia, Cardiopulmonary failure or Diarrhoea. | Entailment | [
3,
6,
8
] | [] | {'Clinical Trial ID': 'NCT00444587', 'Intervention': ['INTERVENTION 1: ', ' Trastuzumab + 2nd Line Chemotherapy', ' Eligible participants were administered trastuzumab 6 mg/kg of body weight (except in Israel, where the dose was 2 mg/kg body weight), IV infusion, every three weeks until disease progression, unaccepta... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 1d7dbb44-049d-4887-8bd6-6aefc77aa1e9 | |
Single | Eligibility | NCT00571987 | occupational exposure to ionizing irradiation will not disqualify a patient from entry to the primary trial. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25,
26
] | [] | {'Clinical Trial ID': 'NCT00571987', 'Intervention': ['INTERVENTION 1: ', ' Margin Status', ' AngioDynamics (previously RITA Med,Inc) radiofrequency delivery system (consisting of a generator and Starburst XL probe): Generator is connected to a single use probe. Probe is inserted into the lumpectomy cavity and heated... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 9b622b9b-3ad3-4cff-acb3-4127d0304de0 | |
Comparison | Eligibility | NCT02673918 | NCT01042938 | African American patients are eligible for both the primary trial and the secondary trial. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15
] | [
0,
4
] | {'Clinical Trial ID': 'NCT02673918', 'Intervention': ['INTERVENTION 1: ', ' Part 1: Home-based Rehabilitation', ' Participants in part 1 and part 2 will receive home-based upper-body rehabilitation with online support: Participants will be given written educational material, in which the physiotherapist marks the exe... | {'Clinical Trial ID': 'NCT01042938', 'Intervention': ['INTERVENTION 1: ', ' Curcumin C3 Complex', ' Patients take 2.0 grams curcumin (four 500mg capsules) three times daily by mouth for prescribed course of radiation treatment (RT) (~4-7 weeks).', 'INTERVENTION 2: ', ' Placebo', ' Patients take 2.0 grams placebo (f... | 825ba6fd-8c08-49d2-941b-3338ef01e7fd |
Single | Eligibility | NCT01730729 | Patients with severe malabsorption disorders are ineligible for the primary trial, even if they are able to receive intravenous (IV) alimentation. | Entailment | [
24,
31,
30
] | [] | {'Clinical Trial ID': 'NCT01730729', 'Intervention': ['INTERVENTION 1: ', ' Treatment (Cabergoline)', ' Patients receive cabergoline oral (PO) twice weekly for weeks 1-4. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.', ' cabergoline: Given orally'], 'Eligibility': ['Inc... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 0421750d-66c6-47be-bde7-0c41ee43a28b | |
Comparison | Eligibility | NCT02872103 | NCT02995980 | Adequate renal, hepatic and blood work is required for entry to the primary trial, this includes the following criteria; hemoglobin 11.5 g/dL, aswell as ALT, AST, alkaline phosphatase and total bilirubin < 2.5xULN, and Serum creatinine should be less than 1.7x ULN. These conditions are not explicitly required for the ... | Entailment | [
6,
7
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12
] | {'Clinical Trial ID': 'NCT02872103', 'Intervention': ['INTERVENTION 1: ', ' F-627', ' F-627, 20 mg fixed dose pre-filled syringe, dosed Day 2 of each of 4 chemotherapy cycles.', 'INTERVENTION 2: ', ' Placebo', ' Placebo, pre-filled syringe administered Day 2 of the first chemotherapy cycle; and F-627, 20 mg fixed d... | {'Clinical Trial ID': 'NCT02995980', 'Intervention': ['INTERVENTION 1: ', ' Contrast Enhanced Mammography', ' Contrast-enhanced spectral mammography for the detection breast cancer .', ' DECE mammography: Contrast mammography', 'INTERVENTION 2: ', ' Standard Digital Mammogram', ' Full field digital mammography for... | 95345dbe-446f-4999-8f3e-a429b77ea554 |
Single | Intervention | NCT00376597 | the primary trial all undergo surgery twice, first at 2 weeks and then again a month later. | Contradiction | [
0,
1,
2,
3,
4,
5
] | [] | {'Clinical Trial ID': 'NCT00376597', 'Intervention': ['INTERVENTION 1: ', ' Arm I (Lymphedema Education)', ' Six weeks after surgery, patients receive a brief initial post-operative care session describing lymphedema risk and prevention through oral instruction and written materials. Patients complete physical assess... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | b05fde86-4004-427f-8baf-2ea4a0a535c7 | |
Single | Eligibility | NCT00825734 | Patients with any of the following conditions will be excluded from the primary trial; grade 3 infection, unstable angina or a grade 4 hemorrhage within the last month. | Entailment | [
87,
94,
95,
108,
117,
118,
119,
120
] | [] | {'Clinical Trial ID': 'NCT00825734', 'Intervention': ['INTERVENTION 1: ', ' Sorafenib and Ixabepilone', ' Oral targeted therapy and Systemic Chemotherapy'], 'Eligibility': ['Inclusion Criteria:', ' Age 18 years.', ' Histologically or cytologically confirmed breast cancer diagnosis', ' with metastatic disease. Pat... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 21e24c6c-d282-48fb-8d68-3e723458794e | |
Single | Intervention | NCT00821964 | the primary trial participants apply topical imiquimod to cutaneous lesions once daily every other day for a total of 14 days every 28 day cycle. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7
] | [] | {'Clinical Trial ID': 'NCT00821964', 'Intervention': ['INTERVENTION 1: ', ' Treatment (Biological Therapy, Chemo)', ' Patients receive Abraxane IV over 30 minutes on days 1, 8, and 15 and apply topical imiquimod to cutaneous lesions QD on days 1-4, 8-11, 15-18, and 22-25. Treatment repeats every 28 days for up to 3 c... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | d1e579e2-b057-43da-8a2f-64dad964b789 | |
Comparison | Adverse Events | NCT00093145 | NCT00703326 | Heart-related adverse events were recorded in the secondary trial, but not the primary trial. | Contradiction | [
0,
3
] | [
0,
7,
8,
9,
10
] | {'Clinical Trial ID': 'NCT00093145', 'Intervention': ['INTERVENTION 1: ', ' Albumin-bound Paclitaxel, Carboplatin + Herceptin', ' Participants received albumin-bound paclitaxel, 100 mg/m^2 weekly every 3 out of 4 weeks, carboplatin at an area under the curve (AUC) = 6 every 4 weeks and Herceptin weekly, 4 mg/kg the f... | {'Clinical Trial ID': 'NCT00703326', 'Intervention': ['INTERVENTION 1: ', ' Ramucirumab (IMC-1121B) + Docetaxel', ' Ramucirumab (IMC-1121B) is administered at a dose of 10 milligrams per kilogram (mg/kg) as a 1-hour intravenous infusion on Day 1 of each 21-day cycle.', ' Docetaxel is administered at a dose of 75 mil... | 5ac83a45-db7d-44d1-bf37-9cbf3c8fabb6 |
Single | Adverse Events | NCT01234402 | the primary trial more than 6 different types of cardiac related adverse events. | Entailment | [
0,
4,
5,
6,
7,
8,
9,
10,
13,
17,
18,
19,
20,
21,
22,
23
] | [] | {'Clinical Trial ID': 'NCT01234402', 'Intervention': ['INTERVENTION 1: ', ' Ramucirumab + Capecitabine', ' Participants received 10 milligram per kilogram (mg/kg) Ramucirumab intravenously on day 1 of 21 days cycle along with 1000 milligram per square meter (mg/m^2) of Capecitabine twice daily orally on days 1 to 14 ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | d130c981-f602-4f17-b1cb-11a7ad632b92 | |
Single | Intervention | NCT03329937 | the primary trial Participants received niraparib 200 milligrams (mg) PO once daily for a 28 day cycle, for 2 cycles | Entailment | [
0,
1,
2
] | [] | {'Clinical Trial ID': 'NCT03329937', 'Intervention': ['INTERVENTION 1: ', ' Niraparib 200 mg', " Participants received niraparib 200 milligrams (mg) orally once daily in 28-day treatment cycles. After 2 cycles, participants either underwent surgery, received additional cycles of niraparib (maximum of 6 cycles total),... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | c1f9982f-c4c9-48dc-887a-7ae05f508c21 | |
Single | Adverse Events | NCT00182793 | The majority of patients in the primary trial experienced an adverse event. | Entailment | [
0,
1
] | [] | {'Clinical Trial ID': 'NCT00182793', 'Intervention': ['INTERVENTION 1: ', ' All Patients', ' Patients undergo stem cell collection. Patients receive high-dose melphalan IV with or without trastuzumab (Herceptin®), one day later, patients undergo autologous peripheral blood stem cell (PBSC) transplantation, no more th... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | e966302f-9378-4681-b2c6-9d8b5b5f709f | |
Comparison | Results | NCT02441946 | NCT00325598 | the secondary trial has a much longer duration than the primary trial. | Entailment | [
0,
3
] | [
0,
3
] | {'Clinical Trial ID': 'NCT02441946', 'Intervention': ['INTERVENTION 1: ', ' Abemaciclib + Anastrozole', ' Participants were given 150 mg of abemaciclib orally Q12H plus 1 mg of anastrozole orally QD for 2 weeks.', ' All participants received 150 mg of abemaciclib orally Q12H plus 1 mg of anastrozole orally QD for an... | {'Clinical Trial ID': 'NCT00325598', 'Intervention': ['INTERVENTION 1: ', ' Cohort 1 (36 Gy)', ' 36 Gy in 9 fractions BID x 4 1/2 treatment days', ' Partial Breast Irradiation (PBI)', 'INTERVENTION 2: ', ' Cohort 2 (40 Gy)', ' 40 Gy in 10 fractions BID over 5 treatment days', ' Partial Breast Irradiation (PBI)'],... | 75130da8-77be-45d1-bc32-dfc97c1a1dae |
Comparison | Intervention | NCT00975676 | NCT00632489 | the primary trial uses the same dosage of Triptorelin as the secondary trial uses for Capecitabine and Lapatinib. | Contradiction | [
0,
1,
2,
3,
4,
5
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9
] | {'Clinical Trial ID': 'NCT00975676', 'Intervention': ['INTERVENTION 1: ', ' Triptorelin Plus Tamoxifen', ' Determination of estrogen levels in blood samples from patients being treated with triptorelin plus tamoxifen for 5 years.', 'INTERVENTION 2: ', ' Triptorelin Plus Exemestane', ' Determination of estrogen leve... | {'Clinical Trial ID': 'NCT00632489', 'Intervention': ['INTERVENTION 1: ', ' LBH589 With Capecitabine', ' MTD, LBH589 with Capecitabine', ' LBH589: LBH589 will be evaluated when administered twice weekly at the following possible dose levels: 20 mg, 30 mg, 45 mg, and 60 mg. Capecitabine will be paired with LBH589 and... | c71cbcd6-3786-4b90-8991-b3c6e159ae77 |
Comparison | Intervention | NCT03167359 | NCT01385137 | Hypofractionated Simultaneous Integrated Boost Radiotherapy is used in the secondary trial. but not the primary trial. | Contradiction | [
0,
1,
2,
3
] | [
0,
1,
2,
3,
4,
5
] | {'Clinical Trial ID': 'NCT03167359', 'Intervention': ['INTERVENTION 1: ', ' Participants With Stage 0-III Breast Cancer', ' Women with Stage 0-III breast cancer, treated with breast conserving surgery or mastectomy and clear margins, will receive 15 doses of radiation over three weeks.', ' Hypofractionated Simultane... | {'Clinical Trial ID': 'NCT01385137', 'Intervention': ['INTERVENTION 1: ', ' Arm I (Omega-3-fatty Acid)', ' Patients receive oral omega-3-fatty acid twice daily (BID) or three times daily (TID) for 24 weeks in the absence of disease progression or unacceptable toxicity', 'INTERVENTION 2: ', ' Arm II (Placebo)', ' Pa... | ed48936e-4933-437b-a7ba-e65b4c1fd276 |
Comparison | Adverse Events | NCT02102490 | NCT00768222 | In contrast to the secondary trial, the primary trial did not record any cases of Skin lymphangitis, Bone marrow suppression or Allergic shock. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11
] | {'Clinical Trial ID': 'NCT02102490', 'Intervention': ['INTERVENTION 1: ', ' Abemaciclib', ' 200 mg abemaciclib given orally once every 12 hours for 28 days (1 cycle). Participants may continue to receive treatment until discontinuation criteria are met.'], 'Eligibility': ['Inclusion Criteria.', ' Have a diagnosis of... | {'Clinical Trial ID': 'NCT00768222', 'Intervention': ['INTERVENTION 1: ', ' Chinese Silk Suture', ' Natural, non-absorbable silk suture made from entwined thread from silkworm larva, commercially available in China, used in a simple interrupted transdermal suture pattern', 'INTERVENTION 2: ', ' VICRYL* Plus Suture',... | b01e966e-6624-4740-b477-a8bbbd8eec50 |
Single | Adverse Events | NCT00820872 | Diarrhea was the most common adverse event in cohort 1 of the primary trial. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12
] | [] | {'Clinical Trial ID': 'NCT00820872', 'Intervention': ['INTERVENTION 1: ', ' Group 1', ' Patients receive docetaxel IV over 60 minutes and carboplatin IV over 30 minutes on day 1, trastuzumab (Herceptin®) IV over 30-90 minutes on days 1, 8, and 15, and oral lapatinib ditosylate on days 1-21 (TCHL). Treatment with TCHL... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 92acd36d-ea44-4b98-acbc-e51382233089 | |
Single | Eligibility | NCT01401062 | A patient who underwent T-cell transfer therapy in the past 6 months prior, and has fully recovered from the associated toxicities, would be excluded from the primary trial. | Contradiction | [
4,
8
] | [] | {'Clinical Trial ID': 'NCT01401062', 'Intervention': ['INTERVENTION 1: ', ' Arm 1 (Fresolimumab 1 mg/kg)', ' Fresolimumab is administered intravenously (i.v.) at a dose of 1 mg/kg on day 1 of weeks 0, 3, 6, 9 & 12 and radiation administered at 7.5 Gy/fraction in 3 fractions during weeks 1 (to lesion 1) and 7 (to lesi... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 01280892-ca31-4e46-831b-a076426f65e5 | |
Single | Results | NCT00393939 | Median (95% Confidence Interval) Progression-Free Survival (PFS) was over a month higher for patients in the Docetaxel + Sunitinib group of the primary trial than for the Docetaxel group. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17
] | [] | {'Clinical Trial ID': 'NCT00393939', 'Intervention': ['INTERVENTION 1: ', ' Docetaxel + Sunitinib', ' Sunitinib 37.5 milligrams (mg) daily by oral capsule for 2 weeks followed by a 1-week off-treatment period (Schedule 2/1) with docetaxel 75 milligrams per square meter (mg/m^2) every 3 weeks, or sunitinib 37.5 mg dai... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 959bd67a-1b2a-48da-ae44-211cbab4b665 | |
Single | Intervention | NCT01432145 | the primary trial patients are administered cyclophosphamide more often and in higher dosages than Methotrexate and 6-Mercaptopurine. | Contradiction | [
0,
1,
2,
3,
4,
5
] | [] | {'Clinical Trial ID': 'NCT01432145', 'Intervention': ['INTERVENTION 1: ', ' 6-Mercaptopurine and Methotrexate (6MP/MTX)', ' 6-Mercaptopurine: 6MP 75mg/m2 body surface area, administered orally (PO) once a day (od) in the morning 1 hour after eating, on a continuous schedule. One cycle is 28 days. Treatment is given c... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 92923765-76d4-4a27-a240-101690d9fea4 | |
Comparison | Intervention | NCT00429507 | NCT00038467 | Unlike the secondary trial, the primary trial does not administer any medication orally or intravenously. | Contradiction | [
0,
1,
2
] | [
0,
1,
2,
3,
4,
5
] | {'Clinical Trial ID': 'NCT00429507', 'Intervention': ['INTERVENTION 1: ', ' Samarium 153-EDTMP + Stem Cell Transplant', ' Samarium 153-EDTMP tracer dose = 30 millicurie (mCi) intravenous Day 1; or with study drug to bones, receive higher therapy dose of 153 Sm-EDTMP 7-14 days after tracer dose. Stem Cell Transplant D... | {'Clinical Trial ID': 'NCT00038467', 'Intervention': ['INTERVENTION 1: ', ' Exemestane', ' Participants diagnosed with breast cancer who remained disease-free after previously receiving 2 to 3 years of tamoxifen 20 milligram (mg) or 30 mg tablet-in-capsule orally once daily as per standard medical practice, received ... | 437cb2c2-63e8-4d9b-a501-4b6a35db8d2b |
Comparison | Eligibility | NCT02872103 | NCT02995980 | Adequate renal, hepatic and blood work is required for entry to the primary trial and the secondary trial, this includes the following criteria; hemoglobin 11.5 g/dL, aswell as ALT, AST, alkaline phosphatase and total bilirubin < 2.5xULN, and Serum creatinine should be less than 1.7x ULN. | Contradiction | [
6,
7
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12
] | {'Clinical Trial ID': 'NCT02872103', 'Intervention': ['INTERVENTION 1: ', ' F-627', ' F-627, 20 mg fixed dose pre-filled syringe, dosed Day 2 of each of 4 chemotherapy cycles.', 'INTERVENTION 2: ', ' Placebo', ' Placebo, pre-filled syringe administered Day 2 of the first chemotherapy cycle; and F-627, 20 mg fixed d... | {'Clinical Trial ID': 'NCT02995980', 'Intervention': ['INTERVENTION 1: ', ' Contrast Enhanced Mammography', ' Contrast-enhanced spectral mammography for the detection breast cancer .', ' DECE mammography: Contrast mammography', 'INTERVENTION 2: ', ' Standard Digital Mammogram', ' Full field digital mammography for... | 5a5695e8-9b84-42ad-9f34-6dd043153943 |
Single | Eligibility | NCT01847001 | Spanish women with a heart rate of at least 60 beats per minute are eligible for the primary trial. | Entailment | [
0,
1,
2
] | [] | {'Clinical Trial ID': 'NCT01847001', 'Intervention': ['INTERVENTION 1: ', ' Propranolol + Neoadjuvant Chemotherapy', ' Subjects will receive 2 types of chemotherapy regimens plus propranolol treatment.', ' Regimen I, involves paclitaxel (may be substituted with nab-paclitaxel; maybe given with premedication), and', ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 33634c51-0fb9-4de1-966d-14784bca93f8 | |
Comparison | Intervention | NCT02297412 | NCT02667626 | Cohort 2 of the secondary trial and the primary trial are control groups. | Entailment | [
0,
1,
2,
3,
4,
5
] | [
0,
1,
2,
3,
4,
5,
6,
7
] | {'Clinical Trial ID': 'NCT02297412', 'Intervention': ['INTERVENTION 1: ', ' Arm I (Minocycline Hydrochloride)', ' Patients receive minocycline hydrochloride PO BID on days 1-7. Treatment repeats every 7 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.', 'INTERVENTION 2: ', ' ... | {'Clinical Trial ID': 'NCT02667626', 'Intervention': ['INTERVENTION 1: ', ' SCPR Intervention', ' Young breast cancer participants will receive their SCPR and access to additional web-based educational reproductive health information, including resource lists of helpful websites, followed by regular reproductive heal... | 8e46dc77-fa36-4231-a124-0ff6392891a1 |
Single | Intervention | NCT00407888 | Arm 1 of the primary trial receive dose-intensive chemotherapy on a week long cycle up to 12 times in the absence of disease progression or unacceptable toxicity. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9
] | [] | {'Clinical Trial ID': 'NCT00407888', 'Intervention': ['INTERVENTION 1: ', ' Arm I', ' Patients receive dose-intensive chemotherapy comprising doxorubicin hydrochloride IV over 10-15 minutes on day 1, oral cyclophosphamide once daily on days 1-7, and filgrastim subcutaneously on days 2-7. Courses repeat every 7 days f... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | d11b0673-42a9-46c0-887f-d5a9b038264f | |
Single | Eligibility | NCT03197389 | All women (regardless of Reproductive status) must use adequate methods of contraception to be eligible for the primary trial. | Contradiction | [
0,
16,
17,
18
] | [] | {'Clinical Trial ID': 'NCT03197389', 'Intervention': ['INTERVENTION 1: ', ' Cohort A1', ' Cohort A1 will include patients with a triple negative breast tumor. Patients will be treated with one injection of Pembrolizumab (Keytruda®) administered intravenously at 200 mg 10 +/- 4 days before surgery.', ' Pembrolizumab:... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | e08c196a-e3f0-420b-a252-7e2818949038 | |
Comparison | Adverse Events | NCT01901146 | NCT00209092 | Cohort 1 of the primary trial recorded more instances of Neutropenic fever than Cohort 1 of the secondary trial. | Entailment | [
0,
2
] | [
0,
4
] | {'Clinical Trial ID': 'NCT01901146', 'Intervention': ['INTERVENTION 1: ', ' ABP 980', ' Participants received ABP 980 at an initial dose of 8 mg/kg over a 90-minute intravenous (IV) infusion, then 6 mg/kg IV infusion every 3 weeks (Q3W) for 3 additional cycles plus 175 mg/m² paclitaxel Q3W for 4 cycles.', 'INTERVENTI... | {'Clinical Trial ID': 'NCT00209092', 'Intervention': ['INTERVENTION 1: ', ' Arm A:Sequential Therapy', ' Docetaxel will be given at 100mg/m^2 intravenously Day1 every 3 weeks for 4 cycles followed by capecitabine 1000 mg/m^2 twice a day by mouth D1-14 every 3 weeks for 4 cycles (total 8 cycles) (total 24 weeks).', 'I... | 83511f04-e07c-438d-bf1e-f680fa49b384 |
Single | Adverse Events | NCT00290758 | There was one genitourinary adverse events recorded in the primary trial. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17
] | [] | {'Clinical Trial ID': 'NCT00290758', 'Intervention': ['INTERVENTION 1: ', ' Arm A (Genistein)', ' Patients receive oral genistein once daily for up to 6 months.', 'INTERVENTION 2: ', ' Arm B (Placebo)', ' Patients receive oral placebo once daily for up to 6 months.'], 'Eligibility': ['Inclusion Criteria:', ' No kn... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | c06a6571-6bc9-4bc1-b4f5-3e7aa71c8c94 | |
Single | Adverse Events | NCT00475670 | compared to cohort 1 of the primary trial, there are more cases of every observed adverse event in cohort 2. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17
] | [] | {'Clinical Trial ID': 'NCT00475670', 'Intervention': ['INTERVENTION 1: ', ' Trastuzumab Monotherapy', ' Participants received either an initial loading dose of trastuzumab 4 mg/kg, IV, on Day 1, followed by 2 mg/kg, IV, once per week, or an initial loading dose of 8 mg/kg IV on Day 1, followed by 6 mg/kg IV once ever... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 72bb3c6e-66b0-4380-9da2-5a5867d715fd | |
Single | Adverse Events | NCT01365845 | More than 18 participants in the primary trial had radiation dermatitis. | Contradiction | [
3
] | [] | {'Clinical Trial ID': 'NCT01365845', 'Intervention': ['INTERVENTION 1: ', ' Conventional Photon Plan', ' Photon: 50.4 Gray (Gy) to the breast/chest wall and peripheral lymph nodes at 1.8 Gy per fraction', 'INTERVENTION 2: ', ' 3D-Proton/Conventional Plan or 3D-proton Only', ' 3D-Proton/Conventional plan or 3D-proto... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 1b433096-f36a-4205-b16e-f9a370be3d05 | |
Comparison | Intervention | NCT01490892 | NCT02364388 | The intervention in the primary trial requires an injection and two different imaging modalities, whereas the secondary trial provides almost no details in the intervention section. | Entailment | [
0,
1,
2,
3
] | [
0,
1,
2
] | {'Clinical Trial ID': 'NCT01490892', 'Intervention': ['INTERVENTION 1: ', ' 3D HI and SHI of UCA', ' Perflutren injection, suspension (IV)0.25 ml followed by 3D Harmonic imaging (HI) then (IV) 20 micro-l/kg followed by 3D subharmonic imaging (SHI)', ' 3D HI and SHI of UCA: Perflutren injection, suspension (IV)0.25 m... | {'Clinical Trial ID': 'NCT02364388', 'Intervention': ['INTERVENTION 1: ', ' MAESTRO', 'Baseline'], 'Eligibility': ['Inclusion Criteria', ' Female', ' 18 years of age or older', ' Have an undiagnosed suspicious finding which may include more than one solid or complex cystic suspicious mass, classified by CDU as BI-R... | 076ead15-ce03-4c33-9050-1f6eb13764a1 |
Comparison | Adverse Events | NCT00323479 | NCT03078751 | There were more cases of Pulmonary embolisms in the primary trial than the secondary trial. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17
] | {'Clinical Trial ID': 'NCT00323479', 'Intervention': ['INTERVENTION 1: ', ' Anastrozole 1 mg', ' Anastrozole 1 mg once daily'], 'Eligibility': ['Inclusion Criteria:', ' Post menopausal woman with a breast cancer and scheduled for an adjuvant treatment with anastrozole', ' WHO performance status 0, 1 or 2', ' Provi... | {'Clinical Trial ID': 'NCT03078751', 'Intervention': ['INTERVENTION 1: ', ' Ribociclib + Adjuvant Endocrine Therapy (ET)', ' Patients in this arm took Ribociclib in combination with standard adjuvant endocrine therapy. ET was one of these 4: Letrozole, Anastrozole, Exemestane, Tamoxifen (Tamoxifen no longer permitted... | 0d76e3b7-c6ed-48b2-a3c2-4857a9c02f76 |
Single | Results | NCT01042535 | The Maximum Tolerated Dose (MTD) of of 1-methyl-d-tryptophan (indoximod) observed in the primary trial was 800 mg. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12
] | [] | {'Clinical Trial ID': 'NCT01042535', 'Intervention': ['INTERVENTION 1: ', ' Treatment (Vaccine Therapy, 1-methyl-d-tryptophan)', ' Participants receive adenovirus-p53 transduced dendritic cell (Ad.p53-DC) vaccine ID in weeks 1, 3, 5, and 10, and then every 3 weeks for 6 total doses. Participants also receive 1-methyl... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 3e1037fd-cc1e-4229-892f-95d0987d9a68 | |
Comparison | Intervention | NCT00343382 | NCT00798135 | Cohort 2 of the primary trial recieves the same dose of Pilocarpine as cohort 2 of the secondary trial recieves of oral itraconazole. | Contradiction | [
3,
4,
5
] | [
0,
1,
2
] | {'Clinical Trial ID': 'NCT00343382', 'Intervention': ['INTERVENTION 1: ', ' Collective Placebo', ' Patients receive 1 capsule of placebo 2 times per day for 6 weeks and; patients receive 1 capsule of placebo 4 times per day for 6 weeks.', 'INTERVENTION 2: ', ' Pilocarpine 2 Times Per Day', ' Patients receive 5mg of... | {'Clinical Trial ID': 'NCT00798135', 'Intervention': ['INTERVENTION 1: ', ' Itraconazole', ' oral itraconazole 200mg a day until disease progression or unacceptable toxicities.'], 'Eligibility': ['Inclusion Criteria:', ' - Patients must have a pathologically confirmed diagnosis of invasive carcinoma of the breast. -... | f25adbc7-c0a0-44ed-af93-02f4bced7208 |
Comparison | Adverse Events | NCT00394082 | NCT01033032 | the primary trial recorded cases of pleural effusion and Spinal compression fracture, neither of these were observed in the secondary trial. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11
] | {'Clinical Trial ID': 'NCT00394082', 'Intervention': ['INTERVENTION 1: ', ' ABI-007 Plus Bevacizumab', ' ABI-007 is administered on days 1, 8 and 15 at 125 mg/m^2 and bevacizumab is administered on day 1 and 15 at 10 mg/kg of each 28 day cycle. Treatment continues until disease progression or intolerable toxicity. If... | {'Clinical Trial ID': 'NCT01033032', 'Intervention': ['INTERVENTION 1: ', ' Amrubicin', ' Systemic therapy with amrubicin'], 'Eligibility': ['Inclusion Criteria:', ' Females >=18 years of age.', ' Histologic diagnosis of HER2-negative breast cancer. HER-2 negativity must be confirmed by one of the following:', ' F... | 99951bae-37c8-4299-8ec1-4577a97d0b81 |
Single | Eligibility | NCT00149214 | Prior use of Anthracycline drugs for anticancer therapy is prohibted for patients in the primary trial. | Entailment | [
4,
5
] | [] | {'Clinical Trial ID': 'NCT00149214', 'Intervention': ['INTERVENTION 1: ', ' Pemetrexed Plus Doxorubicin, Followed by Docetaxel', ' pemetrexed: 500 mg/m^2, intravenous (IV), every 21 days, 4 cycles (1-4) doxorubicin: 60 mg/m^2, intravenous (IV), every 21 days, 4 cycles (1-4) docetaxel: 100 mg/m^2, intravenous (IV), ev... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | b66b62c4-902d-4e19-929e-2086b349bd93 | |
Comparison | Eligibility | NCT00334802 | NCT00167414 | There is no age limit for either the secondary trial or the primary trial. Patients simply need to be diagnosed with interstitial pneumonia or pulmonary fibrosis to be eligible. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11
] | [
0,
1
] | {'Clinical Trial ID': 'NCT00334802', 'Intervention': ['INTERVENTION 1: ', ' Dose Level 1', ' Gemcitabine: 1000 mg/m2, intravenous (IV), day 1 and day 8 x 2 cycles Paclitaxcel: 175 mg/m2, intravenous (IV), every 21 days x 2 cycles', 'INTERVENTION 2: ', ' Dose Level 2', ' Gemcitabine: 1250 mg/m2, intravenous (IV), da... | {'Clinical Trial ID': 'NCT00167414', 'Intervention': ['INTERVENTION 1: ', ' Hypofractionated Stereotactic Body Radiation Therapy', ' Use of Hypofractionated Stereotactic Body Radiation Therapy for limited metastases with breast cancer primary.', ' Hypofractionated Stereotactic Body Radiation Therapy: Hypofractionate... | c789e79c-a254-4bb1-9d15-73d1726da8a6 |
Single | Adverse Events | NCT02481050 | There is only 1 adverse event in the primary trial that occurred more than once. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13
] | [] | {'Clinical Trial ID': 'NCT02481050', 'Intervention': ['INTERVENTION 1: ', ' Eribulin Mesylate 1.4 mg/m^2', ' Participants with histologically confirmed HER2-negative MBC who were previously treated with 2 to 5 chemotherapy regimens received eribulin mesylate 1.4 mg/m^2, intravenous infusion over 2 to 5 minutes on Day... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 2b182323-9357-486a-87aa-09ddc6230bf1 | |
Single | Results | NCT02162667 | The Herceptin group in the primary trial had a higher number of Patients Achieving Pathological Complete Response than the CT-P6 group. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16
] | [] | {'Clinical Trial ID': 'NCT02162667', 'Intervention': ['INTERVENTION 1: ', ' CT-P6', ' Patient received CT-P6 at an initial dose of 8 mg/kg administered by a single IV infusion on Day 1 of Cycle 1, followed by 6 mg/kg on Day 1 of Cycles 2 through 8 (3-week cycles). Patients also received docetaxel 75 mg/m^2 during cyc... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 9681ec15-7545-455e-ac8c-1052fc199b11 | |
Comparison | Eligibility | NCT00256243 | NCT00721630 | the secondary trial and the primary trial are both taking place at the Memorial Sloan Kettering Cancer Center. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11
] | [
0,
1
] | {'Clinical Trial ID': 'NCT00256243', 'Intervention': ['INTERVENTION 1: ', ' Chemotherapy With GM-CSF', ' Doxorubicin and Cyclophosphamide (AC) Followed by Weekly Carboplatin/Paclitaxel with GM-CSF (day 2-6) This regimen consists of intravenous administration of doxorubicin (Adriamycin) followed by cyclophosphamide (C... | {'Clinical Trial ID': 'NCT00721630', 'Intervention': ['INTERVENTION 1: ', ' Capecitabine + Lapatinib', ' The regimen consists of capecitabine 2,000mg twice daily for 7 days followed by a 7-day rest in combination with lapatinib 1,250mg orally daily.', ' capecitabine, lapatinib: Capecitabine 2,000mg twice daily for 7... | 8ca512c3-72d8-4179-a63e-51d83d76445f |
Single | Intervention | NCT00046891 | cohort 1 of the primary trial recieves 60 mg of Ginkgo Biloba twice daily. | Entailment | [
0,
1,
2
] | [] | {'Clinical Trial ID': 'NCT00046891', 'Intervention': ['INTERVENTION 1: ', ' Ginkgo Biloba', ' Ginkgo Biloba: Patients will take 120 mg per day (60 mg BID)', 'INTERVENTION 2: ', ' Placebo', ' Placebo: Patients will take 1 tablet BID'], 'Eligibility': ['DISEASE CHARACTERISTICS:', ' Newly diagnosed breast cancer', ' ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 171d0a20-8943-4994-a48a-7dff124e62ee | |
Single | Intervention | NCT01923168 | Intervention 1 of the primary trial require participants to take a total of 150 mg alpelisib every two days. | Contradiction | [
0,
1,
2
] | [] | {'Clinical Trial ID': 'NCT01923168', 'Intervention': ['INTERVENTION 1: ', ' Alpelisib + Letrozole', ' Participants took alpelisib 300 mg once daily plus letrozole 2.5 mg once daily.', 'INTERVENTION 2: ', ' Placebo + Letrozole', ' Participants took matching Placebo (of alpelisib 300 mg once daily/buparlisib 100 mg o... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 25cc9a6e-656d-44ee-a301-93f5879407a0 | |
Single | Results | NCT00347919 | 56.9% of the primary trial subjects treated with Lapatinib 1500 mg had no progressive Disease at Week 12. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10
] | [] | {'Clinical Trial ID': 'NCT00347919', 'Intervention': ['INTERVENTION 1: ', ' Cohort 1: Lapatinib 1500 mg', ' Lapatinib 1500 milligrams (mg) administered orally once a day', 'INTERVENTION 2: ', ' Cohort 1: Lapatinib 1000 mg/Pazopanib 400 mg', ' Lapatinib 1000 mg and Pazopanib 400 mg administered orally once a day'], ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | d9b4d4aa-0094-405e-83a3-cf2978cfda38 | |
Single | Intervention | NCT00038467 | The patient groups in the primary trial each receive the same doses of different oral medication, either Tamoxifen or Exemestane. | Contradiction | [
0,
1,
2,
3,
4,
5
] | [] | {'Clinical Trial ID': 'NCT00038467', 'Intervention': ['INTERVENTION 1: ', ' Exemestane', ' Participants diagnosed with breast cancer who remained disease-free after previously receiving 2 to 3 years of tamoxifen 20 milligram (mg) or 30 mg tablet-in-capsule orally once daily as per standard medical practice, received ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | caa55802-329d-4a1f-a9a7-b99afc44fd67 | |
Comparison | Intervention | NCT02525718 | NCT02606708 | Patients in group 1 of the secondary trial and the primary trial receive the same dosage of oral placebo. | Contradiction | [
0,
1,
2,
3
] | [
0,
1,
2,
3
] | {'Clinical Trial ID': 'NCT02525718', 'Intervention': ['INTERVENTION 1: ', ' Placebo', ' Subjects will be randomly selected to receive saline (placebo), administered to the breast area to cover the intercostal nerves supplying the breast tissue during surgery.', ' Saline: If randomized to this arm, subjects will rece... | {'Clinical Trial ID': 'NCT02606708', 'Intervention': ['INTERVENTION 1: ', ' Accelerated Intensity Modulated Radiation Therapy (AIMRT)', ' All patients shall receive a total of 40.5 Gy to the entire breast in 2.7 Gy/fraction x 15 fractions, Monday to Friday for 3 weeks delivered prone in uniform daily doses through IM... | 6df9ec3b-43ba-442a-a4f5-4ce3cdb7a2a0 |
Comparison | Intervention | NCT00262834 | NCT01106898 | In the secondary trial Her-2 neu positive breast cancer patients receive additional maintenance therapy compared to other patients. Whereas all the primary trial participants receive the same treatment. | Entailment | [
0,
1,
2
] | [
0,
1,
2,
3,
4
] | {'Clinical Trial ID': 'NCT00262834', 'Intervention': ['INTERVENTION 1: ', ' Vorinostat', ' Women in the vorinostat group were scheduled to receive 6 doses of oral vorinostat at 300 mg twice daily (bid), with the last dose administered by study personnel approximately 2 hours before the scheduled breast surgery (or bi... | {'Clinical Trial ID': 'NCT01106898', 'Intervention': ['INTERVENTION 1: ', ' Treatment (Chemotherapy With or Without Maintenance Therapy)', ' SYSTEMIC CHEMOTHERAPY: Patients receive cyclophosphamide IV over 1 hour and paclitaxel IV over 3 hours on day 1. Treatment repeats every 14 days for 6 courses in the absence of ... | 0880bb0b-9e8d-4fce-8795-2ec6526d9bfb |
Single | Intervention | NCT02780713 | Both cohorts of the primary trial are administered the same drugs in different doses . | Contradiction | [
0,
1,
2,
3,
4,
5
] | [] | {'Clinical Trial ID': 'NCT02780713', 'Intervention': ['INTERVENTION 1: ', ' Treatment Period 1', ' Participants received AZD9496 - Variant A (100 mg).', 'INTERVENTION 2: ', ' Treatment Period 2', ' Participants received AZD9496 - Reference (100 mg).'], 'Eligibility': ['Inclusion Criteria:', ' Provision of signed a... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | baea8eb9-a6e7-4473-9b4b-28a4fdb531ad | |
Single | Eligibility | NCT00054275 | A patient with severe anginal syndrome but angiographically normal coronary arteries would be unable to participate in the primary trial. | Entailment | [
33,
35
] | [] | {'Clinical Trial ID': 'NCT00054275', 'Intervention': ['INTERVENTION 1: ', ' Docetaxel and OSI-774', ' docetaxel IV over 1 hour once weekly for 3 weeks and oral erlotinib once daily'], 'Eligibility': ['DISEASE CHARACTERISTICS:', ' Histologically confirmed stage IV or recurrent adenocarcinoma of the breast', ' Measur... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 01f89936-1621-4dd5-93b7-8b0c64b397fd | |
Single | Intervention | NCT00320411 | the primary trial participants must take 6 tablets of Lapatinib Monotherapy (250mg) PO once daily. | Entailment | [
0,
1,
2
] | [] | {'Clinical Trial ID': 'NCT00320411', 'Intervention': ['INTERVENTION 1: ', ' Lapatinib Monotherapy', ' Lapatinib: 1500 mg (six 250 mg tablets) orally once daily'], 'Eligibility': ['Inclusion Criteria:', ' A subject will be considered eligible for inclusion in this study only if all of the following criteria apply:', ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | ee7fe82e-de91-45c7-bd12-bff5d6c887a3 | |
Comparison | Adverse Events | NCT00266110 | NCT00879086 | the primary trial had a much higher rate of adverse events than the secondary trial. | Contradiction | [
0,
1,
2,
3,
4
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25,
26,
27
] | {'Clinical Trial ID': 'NCT00266110', 'Intervention': ['INTERVENTION 1: ', ' Dendritic Cell Vaccine', ' Therapeutic autologous dendritic cells (Dendritic Cell Vaccine) i.d. injection, 20 x 106 DCs given per treatment Trastuzumab infusion Vinorelbine ditartrate infusion', ' sargramostim: All patients will receive Leuk... | {'Clinical Trial ID': 'NCT00879086', 'Intervention': ['INTERVENTION 1: ', ' Eribulin Mesylate', ' Eribulin mesylate was given at a dose of 1.4 mg/m^2 as a 2 to 5 minute IV bolus on Days 1 and 8 of a 21-day cycle during the Treatment and Extension Phases. The Treatment Phase included six cycles. Following the sixth cy... | 888a8d39-3ad6-401e-acf2-cf5e01a73bf2 |
Single | Adverse Events | NCT00679211 | 1 patient in the primary trial presented a fever, in addition to either a cough or a sore throat. | Entailment | [
0,
12
] | [] | {'Clinical Trial ID': 'NCT00679211', 'Intervention': ['INTERVENTION 1: ', ' 6 Months of Follow-up', ' Trastuzumab emtansine (T-DM1) was administered to participants at a dose of 3.6 mg/kg by intravenous (IV) infusion every 3 weeks until documented disease progression, unmanageable toxicity, or study termination.', 'I... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 13466cbb-9f78-46ff-a983-09e2e9ad5a2c | |
Single | Results | NCT00374322 | the primary trial results show that Participants receiving lapatinib 1500 milligrams (mg) orally were more likely to achieve DFS at 5 years than placebo patients, however, there was less than a 30% difference in DFS rate between the two cohorts. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19
] | [] | {'Clinical Trial ID': 'NCT00374322', 'Intervention': ['INTERVENTION 1: ', ' Lapatinib 1500 mg', ' Participants received lapatinib 1500 milligrams (mg) orally once daily. Treatment was continued for a maximum of 12 months or until disease recurrence or development of a second primary cancer, withdrawal from study trea... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 0beaef44-a39a-462c-a084-d3f824857673 | |
Single | Intervention | NCT01432145 | the primary trial patients are administered 6-Mercaptopurine more often and in higher dosages than Methotrexate. | Entailment | [
0,
1,
2,
3,
4,
5
] | [] | {'Clinical Trial ID': 'NCT01432145', 'Intervention': ['INTERVENTION 1: ', ' 6-Mercaptopurine and Methotrexate (6MP/MTX)', ' 6-Mercaptopurine: 6MP 75mg/m2 body surface area, administered orally (PO) once a day (od) in the morning 1 hour after eating, on a continuous schedule. One cycle is 28 days. Treatment is given c... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | 8e45da73-f016-4ca0-b106-a3fabc960b36 | |
Comparison | Intervention | NCT01420146 | NCT00077376 | the primary trial and the secondary trial are both single arm clinical trials. | Entailment | [
0,
1,
2
] | [
0,
1,
2,
3
] | {'Clinical Trial ID': 'NCT01420146', 'Intervention': ['INTERVENTION 1: ', ' Zr89-trastuzumab PET/CT', ' Zr89-trastuzumab (trastuzumab labelled with zirconium 89) for PET/CT single arm'], 'Eligibility': ['Inclusion criteria:', ' All patients selected for this imaging study are patients scheduled to start trastuzumab-... | {'Clinical Trial ID': 'NCT00077376', 'Intervention': ['INTERVENTION 1: ', ' Trastuzumab/Ixabepilone/Carboplatin', ' During the induction phase, patients were treated with Ixabepilone (BMS-247550) 15mg/m2 intravenously (IV) followed by carboplatin (AUC=2 IV) on days 1, 8 and 15 of a 28-day cycle for a maximum of 6 cyc... | 37dc56a4-4756-4ab0-8055-7637bf579740 |
Comparison | Intervention | NCT02115607 | NCT01823107 | Patients in the primary trial receive an Infusion of 3 ml Perflutren Lipid Microspheres at a rate of approximately 3ml/min, whereas in the secondary trial subjects are implanted with a permanent Meso BioMatrix Acellular Peritoneum Matrix. | Contradiction | [
0,
1,
2,
3
] | [
0,
1,
2
] | {'Clinical Trial ID': 'NCT02115607', 'Intervention': ['INTERVENTION 1: ', ' Definity Infusion', ' Infusion of Definity (Perflutren Lipid Microspheres)', ' Definity infusion: 3 ml of Perflutren Lipid Microspheres (Definity) mixed in 50 ml of saline is infused at a rate of approximately 4ml/min'], 'Eligibility': ['Inc... | {'Clinical Trial ID': 'NCT01823107', 'Intervention': ['INTERVENTION 1: ', ' Meso BioMatrix Acellular Peritoneum Matrix', ' All subjects had the Meso BioMatrix Acellular Peritoneum Matrix implanted along with a tissue expander during the first stage of breast reconstruction. After tissue expansion, the tissue expander... | 65e370b7-7726-477e-8730-8cea734d1609 |
Single | Adverse Events | NCT03012477 | One patient in the primary trial experienced a thromboembolic event, a condition associated with a high degree of morbidity and mortality. However, the most common adverse event was Diarrhea. | Entailment | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11
] | [] | {'Clinical Trial ID': 'NCT03012477', 'Intervention': ['INTERVENTION 1: ', ' Cisplatin + AZD1775', ' Treatment will consist of one cycle of cisplatin monotherapy (cisplatin 75 mg/m2 IV x1) followed by combination therapy of AZD1775 plus cisplatin starting 21 days(1 cycle) later.', ' AZD1775 will be administered 200 m... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | affdd551-15e2-4a47-8c20-209cc01570ec | |
Comparison | Intervention | NCT02176083 | NCT03061175 | Neither the primary trial or NCT0306117 use chemotherapy, adverse event management courses or radiotherapy in their intervention. | Contradiction | [
0,
1,
2,
3,
4,
5,
6
] | [
0,
1,
2,
3,
4,
5,
6,
7,
8
] | {'Clinical Trial ID': 'NCT02176083', 'Intervention': ['INTERVENTION 1: ', ' Intervention', ' Text message management prompts: YBCS will receive text message prompts on how to manage hot flashes and vaginal dryness', ' Text message management prompts', 'INTERVENTION 2: ', ' Control', ' Control YBCS will not receive... | {'Clinical Trial ID': 'NCT03061175', 'Intervention': ['INTERVENTION 1: ', ' Arm I (Web-Based CPM-DA)', ' Patients receive a website address, a secure username and password, and instructions for using the web-based CPM-DA.', ' Internet-Based Intervention: Receive web-based CPM-DA', ' Survey Administration: Ancillary... | 2152f503-4fa4-4f32-b766-a05a4c69742f |
Single | Adverse Events | NCT01300351 | At least 1 participant in each cohort of the primary trial showed signs of poor liver function. | Contradiction | [
0,
7
] | [] | {'Clinical Trial ID': 'NCT01300351', 'Intervention': ['INTERVENTION 1: ', ' Fulvestrant 500 mg', ' Fulvestrant 500 mg intramuscular (im) every 28 (± 3) days plus an additional 500 mg on Day 15 (± 3) of first month only', 'INTERVENTION 2: ', ' Fulvestrant 250 mg', ' Fulvestrant 250 mg im every 28 (± 3) days'], 'Elig... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | a7903e59-9620-457a-8d83-eb6eb5dd8a2b | |
Single | Eligibility | NCT00186121 | Patients with E2 outside the premenopausal range are ineligible for the primary trial. | Entailment | [
5
] | [] | {'Clinical Trial ID': 'NCT00186121', 'Intervention': ['INTERVENTION 1: ', ' Anastrozole + Goserelin', ' Participants received goserelin 3.6 mg subcutaneously monthly. Beginning on Day 22 after the first dose of goserelin, participants began taking anastrozole 1 mg orally daily.'], 'Eligibility': ['INCLUSION CRITERIA'... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | dc7e7fbe-eed9-4307-b584-30ecaeb77c95 | |
Single | Intervention | NCT02006979 | Neither cohort of the primary trial need to perform low intensity exercise prior to each cycle of anthracyclines. | Entailment | [
0,
1,
2,
3,
4,
5
] | [] | {'Clinical Trial ID': 'NCT02006979', 'Intervention': ['INTERVENTION 1: ', ' Exercise', ' an acute bout of exercise performed 24 hours prior to each cycle of anthracyclines and no exercise for 48 hours post exercise', 'INTERVENTION 2: ', ' Usual Care', ' no exercise for 72 hours prior or 48 hours post each cycle of ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | a34c6194-b6d9-49c3-8ddb-72de10c8a18c | |
Single | Adverse Events | NCT01120184 | At least 1 patient in cohort 1 of the primary trial suffered from a coagulation disorder. | Entailment | [
0,
6
] | [] | {'Clinical Trial ID': 'NCT01120184', 'Intervention': ['INTERVENTION 1: ', ' Trastuzumab + Taxane', " Participants received trastuzumab plus either docetaxel or paclitaxel. The regimen was chosen at the investigator's discretion. Option 1: trastuzumab 8 mg/kg via IV infusion on Day 1 of Cycle 1, then 6 mg/kg IV on Day... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | da00532d-57a8-4fe2-a2de-acc525161fd9 | |
Comparison | Eligibility | NCT02511730 | NCT00193206 | Patients with prior chemotherapy are excluded from the secondary trial and the primary trial. | Contradiction | [
0,
1,
2,
3
] | [
0,
6
] | {'Clinical Trial ID': 'NCT02511730', 'Intervention': ['INTERVENTION 1: ', ' FFDM Plus DBT', ' Breast Images with FFDM and DBT', ' FFDM Plus DBT: Fujifilm Aspire Cristalle System', 'INTERVENTION 2: ', ' FFDM', ' Breast Images with FFDM alone', ' FFDM: Fujifilm Aspire Cristalle System'], 'Eligibility': ['Inclusion ... | {'Clinical Trial ID': 'NCT00193206', 'Intervention': ['INTERVENTION 1: ', ' Intervention', ' Systemic Therapy', ' ABI-007 : ABI-007 175 mg/m2 D1 q 14 days x 6 cycles', ' Epirubicin : Epirubicin 50 mg/m2 D1 q 14 days x 6 cycles', ' Gemcitabine : Gemcitabine 2000 mg/m2 IV D1 q 14 days x 6 cycles'], 'Eligibility': ['... | f90364e9-caee-4075-b444-2db1bf846d3a |
Single | Eligibility | NCT01908101 | Prior exposure to doxatel is obligatory for patients in the primary trial. | Contradiction | [
0,
1,
2
] | [] | {'Clinical Trial ID': 'NCT01908101', 'Intervention': ['INTERVENTION 1: ', ' Treatment (Eribulin Mesylate)', ' Patients receive eribulin mesylate IV over 2-5 minutes on days 1, 8, and 15. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.', ' Eribulin Mesylate: Given IV', ' ... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | deb78676-8f04-44c4-a5f6-389740d8a268 | |
Single | Adverse Events | NCT00591851 | There were 4 different cardiac adverse events recorded in cohort 1 of the primary trial. | Contradiction | [
0,
1,
2,
3,
4,
5,
6,
7,
8,
9,
10,
11,
12
] | [] | {'Clinical Trial ID': 'NCT00591851', 'Intervention': ['INTERVENTION 1: ', ' AC Followed by Paclitaxel + Trastuzumab', ' Doxorubicin and Cyclophosphamide (60/600 mg/m2) X 4 followed by Paclitaxel (175 mg/m2) X 4 every 2 weekly with pegfilgrastim (6mg on day 2) + Trastuzumab x 1 year.'], 'Eligibility': ['Inclusion Crit... | {'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''} | a06d1ca5-c890-4157-b1d2-0b70fd0092bd |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.